This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
- Supplementary File 1:
ZIP-Document (ZIP, 640 KiB)
Noblejas-López, M.d.M.; Gandullo-Sánchez, L.; Galán-Moya, E.M.; López-Rosa, R.; Tébar-García, D.; Nieto-Jiménez, C.; Gómez-Juárez, M.; Burgos, M.; Pandiella, A.; Ocaña, A. Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer. Int. J. Mol. Sci. 2022, 23, 5476. https://doi.org/10.3390/ijms23105476
Noblejas-López MdM, Gandullo-Sánchez L, Galán-Moya EM, López-Rosa R, Tébar-García D, Nieto-Jiménez C, Gómez-Juárez M, Burgos M, Pandiella A, Ocaña A. Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer. International Journal of Molecular Sciences. 2022; 23(10):5476. https://doi.org/10.3390/ijms23105476
Chicago/Turabian StyleNoblejas-López, María d.M., Lucía Gandullo-Sánchez, Eva M. Galán-Moya, Raquel López-Rosa, David Tébar-García, Cristina Nieto-Jiménez, Mónica Gómez-Juárez, Miguel Burgos, Atanasio Pandiella, and Alberto Ocaña. 2022. "Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer" International Journal of Molecular Sciences 23, no. 10: 5476. https://doi.org/10.3390/ijms23105476